Complete Response Letter For Outlook’s Bevacizumab Is Both Straightforward And Elusive

Low On Cash, Rush Is On To Clarify US FDA’s Concerns

 
• By Mandy Jackson
  
Close up cropped shot, face of senior woman eye looking straight, into distance.
Outlook will request at Type A meeting with the FDA to discuss the CRL • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews